- Recent Funding
- Investors
- Woodline Partners
Woodline Partners portfolio
Woodline Partners has 7 portfolio companies on record at Recent Funding, with 2 investments in the last 12 months.
About this page
It led 1 of the 6 rounds it joined. Its most recent investment on record is Skyryse's $300M Series B+ round in February 2026, alongside Fidelity Management & Research Company, Qatar Investment Authority, BAM Elevate and 7 others. By category, its portfolio leans toward Health and bio (4) and Commerce and retail (2). It has co-invested with ArrowMark Partners, Durable Capital Partners and Qatar Investment Authority, most often ArrowMark Partners (2 rounds).
What Woodline Partners invests in
- Health and bio · 4 · 57%
- Commerce and retail · 2 · 29%
- Legal and compliance · 1 · 14%
- Robotics and hardware · 1 · 14%
- Defense and security · 1 · 14%
- Cybersecurity · 1 · 14%
- Logistics and mobility · 1 · 14%
- Data and analytics · 1 · 14%
Woodline Partners recent investments
| Company | Round | Date | Alongside |
|---|---|---|---|
| Series B+ · $300M | Fidelity Management & Research Company (lead), Qatar Investment Authority, BAM Elevate +7 | ||
| Series B+ · $100M | Alumni Ventures, Eclipse (lead), Alsop Louie Partners +2 | ||
| Series B+ · $30M | G9 Ventures, Bain Capital Ventures, Capital F +3 | ||
| Series B+ · $61M | Rewe Group, Grazia Equity, Sazaby League +6 | ||
| Series B+ · $215M | Tao Capital, TCG Crossover (lead), Vertex Pharmaceuticals +6 | ||
| Series B+ · $88.5M · lead | DCVC Bio, Droia Ventures, Deep Track Capital +6 |
How Woodline Partners invests
| Stage | Deals | Capital in rounds |
|---|---|---|
| Series B+ | 6 100% | $794.5M |
Woodline Partners portfolio companies
SSkyryse$300MSeries B+ · Feb 2026
UUrsa Major$100MSeries B+ · Nov 2025
AArchive$30MSeries B+ · Feb 2025
FFormo$61MSeries B+ · Oct 2024
AArbor Biotechnologies$215MSeries B+ · Nov 2021
FFrontier Medicines$88.5MSeries B+ · Jul 2021
MMirador Therapeuticsbacker
| Company | Round with Woodline Partners | Total raised | Latest raise |
|---|---|---|---|
Legal and compliance |
Series B+ · $300M | $513M | Feb 3, 2026 Series B+ |
Defense and security |
Series B+ · $100M | $440.8M | Nov 18, 2025 Series B+ |
Commerce and retail |
Series B+ · $30M | $50M | Feb 4, 2025 Series B+ |
Commerce and retail |
Series B+ · $61M | $111M | Oct 9, 2024 Series B+ |
Health and bio |
Series B+ · $215M | $289M | Mar 18, 2025 Series B+ |
Health and bio |
Series B+ · $88.5M · lead | $235.5M | Aug 28, 2025 Series B+ |
Health and bio |
backer | $650M | Jan 13, 2026 Series B+ |
Most frequent co-investors
AArrowMark Partners2 shared rounds · last Feb 3, 2026
DDurable Capital Partners1 shared round · last Feb 3, 2026
QQatar Investment Authority1 shared round · last Feb 3, 2026
AAtreides Management1 shared round · last Feb 3, 2026
- FFidelity Management & Research Company1 shared round · last Feb 3, 2026
BBaron Capital1 shared round · last Feb 3, 2026
PPositive Sum1 shared round · last Feb 3, 2026
BBAM Elevate1 shared round · last Feb 3, 2026
AAutopilot Ventures1 shared round · last Feb 3, 2026
RRokos Capital Management1 shared round · last Feb 3, 2026
AAlumni Ventures1 shared round · last Nov 18, 2025
EEclipse1 shared round · last Nov 18, 2025
Similar investors
IIntrepid Growth Partners7 companies · 6 deals in 12 mo
..406 Ventures7 companies · 5 deals in 12 mo
IInnovestor7 companies · 4 deals in 12 mo
TTCG Crossover7 companies · 4 deals in 12 mo
TTesi7 companies · 4 deals in 12 mo
UUniversity of Oxford7 companies · 4 deals in 12 mo
Investors whose portfolios on Recent Funding center on the same category (Health and bio).
How this is counted
Share is of the 6 rounds on Recent Funding that name Woodline Partners. Rounds with no announced date are left out of the year split, and "round" is a round whose stage is not on file.
Portfolio companies are the companies on Recent Funding with a round that lists Woodline Partners, which is a subset of its real portfolio. API: /api/v1/investors/woodline-partners (get a free API key). More: the most active VC firms and new venture capital funds.